线粒体生物合成在糖尿病心肌病中的研究进展

doi:10.19586/j.2095-2341.2023.0128

生物技术进展 ›› 2024, Vol. 14 ›› Issue (2): 221-227.DOI: 10.19586/j.2095-2341.2023.0128

线粒体生物合成在糖尿病心肌病中的研究进展

王钰淇¹(), 王心雨¹, 王颖凡², 孟远翠², 严喜章¹, 常盼³()

^1.西安医学院第二临床医学院麻醉系，西安 710038
^2.西安医学院第二附属医院新生儿科，西安 710038
^3.西安医学院第二附属医院心内科，西安 710038

收稿日期:2023-10-17 接受日期:2023-12-12 出版日期:2024-03-25 发布日期:2024-04-17
通讯作者: 常盼
作者简介:王钰淇 E-mail: wyq01252021@163.com；
基金资助:
国家自然科学基金项目(82300407);陕西省科技厅自然基础重点项目(2023-JC-ZD-55);西安医学院大学生创新创业训练计划项目(S202311840063);陕西省教育厅产业化项目(23JC059)

Research Progress of Mitochondrial Biosynthesis in Diabetes Cardiomyopathy

Yuqi WANG¹(), Xinyu WANG¹, Yingfan WANG², Yuancui MENG², Xizhang YAN¹, Pan CHANG³()

^1.Department of Anesthesiology，Second Clinical Medical College，Xi'an Medical College，Xi'an 710038，China
^2.Department of Neonatology，Second Affiliated Hospital of Xi'an Medical College，Xi'an 710038，China
^3.Department of Cardiology，Second Affiliated Hospital of Xi'an Medical College，Xi'an 710038，China

Received:2023-10-17 Accepted:2023-12-12 Online:2024-03-25 Published:2024-04-17
Contact: Pan CHANG

摘要/Abstract

摘要：

糖尿病心肌病（diabetic cardiomyopathy，DCM）是糖尿病（diabetesmellitus，DM)最严重和最常见的并发症之一，其发病机制尚未明确。越来越多的研究表明，线粒体稳态与DCM病程的发展密切相关。线粒体生物合成作为线粒体稳态的重要组成部分，参与DCM的发生发展过程。通过调节线粒体生物合成相关的分子机制以改善线粒体功能，有望做为防治DCM的新靶点。根据近年来国内外文献，总结了线粒体生物合成在DCM中的作用机制和研究进展，以期为DCM的预防和治疗提供参考。

关键词: 糖尿病心肌病, 线粒体生物合成, 降糖药, 线粒体稳态

Abstract:

Diabetic cardiomyopathy （DCM） is one of the most serious and common complications of diabetesmellitus （DM）， and its pathogenesis is not well understood. A growing body of studies has shown that mitochondrial homeostasis is closely related to the development of DCM. Mitochondrial biosynthesis， as an important part of mitochondrial homeostasis， is involved in the occurrence and development of DCM. Improving mitochondrial function by regulating molecular mechanisms related to mitochondrial biosynthesis may be a new target for the prevention and treatment of DCM. Based on the literature at home and abrod in recent years， the mechanism and research progress of mitochondrial biosynthesis in DCM were summarized in order to provide a reference for the prevention and treatment of DCM.

Key words: diabetic cardiomyopathy, mitochondrial biosynthesis, hypoglycemics, mitochondrial homeostasis

中图分类号:

Q731

王钰淇, 王心雨, 王颖凡, 孟远翠, 严喜章, 常盼. 线粒体生物合成在糖尿病心肌病中的研究进展[J]. 生物技术进展, 2024, 14(2): 221-227.

Yuqi WANG, Xinyu WANG, Yingfan WANG, Yuancui MENG, Xizhang YAN, Pan CHANG. Research Progress of Mitochondrial Biosynthesis in Diabetes Cardiomyopathy[J]. Current Biotechnology, 2024, 14(2): 221-227.

图/表 1

参考文献 49

1	SUN H, SAEEDI P, KARURANGA S, et al.. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J/OL]. Diabetes Res. Clin. Pract., 2022, 183: 109119[2021-12-06]. .
2	廖敏,杨洛,王珍,等.松果菊苷对db/db糖尿病小鼠心肌的保护作用[J].生物技术进展,2022,12(1):129-134.
	LIAO M, YANG L, WANG Z, et al.. Protective effect of echinacoside on myocardium in db/db diabetic mice[J]. Curr. Biotechnol., 2022, 12(1): 129-134.
3	ZHENG H, ZHU H, LIU X, et al.. Mitophagy in diabetic cardiomyopathy: roles and mechanisms[J/OL]. Front. Cell Dev. Biol., 2021, 9: 750382[2021-09-27]. .
4	廖敏,杨洛,王珍,等.糖尿病心肌病发病机制的研究进展[J].生物技术进展,2021,11(6):700-704.
	LIAO M, YANG L, WANG Z, et al.. Research progress on the pathogenesis of diabetic cardiomyopathy[J]. Curr. Biotechnol., 2021, 11(6): 700-704.
5	PETERSON L R, GROPLER R J. Metabolic and molecular imaging of the diabetic cardiomyopathy[J]. Circ. Res., 2020, 126(11): 1628-1645.
6	WU N N, ZHANG Y, REN J. Mitophagy, dynamicsmitochondrial, and homeostasis in cardiovascular aging[J/OL]. Oxid. Med. Cell. Longev., 2019, 2019: 9825061[2019-11-04]. .
7	BALABAN R S. Regulation of oxidative phosphorylation in the mammalian cell[J]. Am. J. Physiol., 1990, 258(Pt 1): 377-389.
8	ZHOU H, DAI Z, LI J, et al.. TMBIM6 prevents VDAC1 multimerization and improves mitochondrial quality control to reduce sepsis-related myocardial injury[J/OL]. Metabolism, 2023, 140: 155383[2023-01-02]. .
9	PLOUMI C, DASKALAKI I, TAVERNARAKIS N. Mitochondrial biogenesis and clearance: a balancing act[J]. FEBS J., 2017, 284(2): 183-195.
10	LI L, ZHANG Y, CHEN Z, et al.. SIRT1-dependent mitochondrial biogenesis supports therapeutic effects of vidarabine against rotenone-induced neural cell injury[J/OL]. Heliyon, 2023, 9(11): e21695[2023-10-26]. .
11	CHANG X, LI Y, CAI C, et al.. Mitochondrial quality control mechanisms as molecular targets in diabetic heart[J/OL]. Metabolism, 2022, 137: 155313[2022-09-17]. .
12	KIYUNA L A, CANDIDO D S, BECHARA L R G, et al.. 4-hydroxynonenal impairs miRNA maturation in heart failure via Dicer post-translational modification[J]. Eur. Heart J., 2023, 44(44): 4696-4712.
13	FONTANA F, MACCHI C, ANSELMI M, et al.. PGC1-α-driven mitochondrial biogenesis contributes to a cancer stem cell phenotype in melanoma[J/OL]. Biochim. Biophys. Acta Mol. Basis Dis., 2024, 1870(1): 166897[2023-09-25]. .
14	MAISSAN P, MOOIJ E J, BARBERIS M. Sirtuins-mediated system-level regulation of mammalian tissues at the interface between metabolism and cell cycle: a systematic review[J/OL]. Biology, 2021, 10(3): 194[2021-03-04]. .
15	ZHANG J, LI J, LIU Y, et al.. Effect of resveratrol on skeletal slow-twitch muscle fiber expression via AMPK/PGC-1α signaling pathway in bovine myotubes[J/OL]. Meat Sci., 2023, 204: 109287[2023-07-20]. .
16	WANG W, CHEN S, XU S, et al.. Jianpi Shengqing Huazhuo Formula improves abnormal glucose and lipid metabolism in obesity by regulating mitochondrial biogenesis[J/OL]. J. Ethnopharmacol., 2024, 319(Pt 1): 117102[2023-09-03]. .
17	ŻULIŃSKA S, STROSZNAJDER A K, STROSZNAJDER J B. The role of synthetic ligand of PPARα in regulation of transcription of genes related to mitochondria biogenesis and dynamic in an animal model of Alzheimer's disease[J]. Folia Neuropathol., 2023, 61(2): 138-143.
18	WANG L, BI X, HAN J. Silencing of peroxisome proliferator-activated receptor-alpha alleviates myocardial injury in diabetic cardiomyopathy by downregulating 3-hydroxy-3-methylglutaryl-coenzyme A synthase 2 expression[J]. IUBMB Life, 2020, 72(9): 1997-2009.
19	PACKER M. Autophagy-dependent and-independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs[J/OL]. Cardiovasc. Diabetol., 2020, 19(1): 62[2020-05-13]. .
20	ZHANG Z, ZHANG X, MENG L, et al.. Pioglitazone inhibits diabetes-induced atrial mitochondrial oxidative stress and improves mitochondrial biogenesis, dynamics, and function through the PPAR-γ/PGC-1α signaling pathway[J/OL]. Front. Pharmacol., 2021, 12: 658362[2021-06-14]. .
21	PUIGSERVER P, WU Z, PARK C W, et al.. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis[J]. Cell, 1998, 92(6): 829-839.
22	TAO L C, WANG T T, ZHENG L, et al.. The role of mitochondrial biogenesis dysfunction in diabetic cardiomyopathy[J]. Biomol. Ther., 2022, 30(5): 399-408.
23	SHELBAYEH O A, ARROUM T, MORRIS S, et al.. PGC-1α is a master regulator of mitochondrial lifecycle and ROS stress response[J/OL]. Antioxidants, 2023, 12(5): 1075[2023-05-10]. .
24	MUSHTAQ I, BASHIR Z, SARWAR M, et al.. N-acetyl cysteine, selenium, and ascorbic acid rescue diabetic cardiac hypertrophy via mitochondrial-associated redox regulators[J/OL]. Molecules, 2021, 26(23): 7285[2021-11-30]. .
25	HU T, WU Q, YAO Q, et al.. PRDM16 exerts critical role in myocardial metabolism and energetics in type 2 diabetes induced cardiomyopathy[J/OL]. Metabolism, 2023, 146: 155658[2023-07-09]. .
26	梁传财,易鹏,邱波.AMPK/SIRT1/PPARγ/PGC1α轴及其相关因子在骨关节炎脂质代谢中的作用[J].生物技术进展,2021,11(6):718-723.
	LIANG C C, YI P, QIU B. Effects of AMPK/SIRT1/PPARγ/PGC1α axis and related factors on lipid metabolism in osteoarthritis[J]. Curr. Biotechnol., 2021, 11(6): 718-723.
27	LEE T W, BAI K J, LEE T I, et al.. PPARs modulate cardiac metabolism and mitochondrial function in diabetes[J/OL]. J. Biomed. Sci., 2017, 24(1): 5[2017-01-10]. .
28	KHAN D, ARA T, RAVI V, et al.. SIRT6 transcriptionally regulates fatty acid transport by suppressing PPARγ[J/OL]. Cell Rep., 2021, 35(9): 109190[2021-06-01]. .
29	CEFALO C M A, CINTI F, MOFFA S, et al.. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives[J/OL]. Cardiovasc. Diabetol., 2019, 18(1): 20[2019-02-28]. .
30	WEI D, LIAO L, WANG H, et al.. Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPARα in vivo and in vitro [J/OL]. Life Sci., 2020, 247: 117414[2020-02-06]. .
31	REIFSNIDER O S, KANSAL A R, GANDHI P K, et al.. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease[J/OL]. BMJ Open Diabetes Res. Care, 2021, 9(1): e001313[2021-05-09]. .
32	KIM J H, LEE M, KIM S H, et al.. Sodium-glucose cotransporter 2 inhibitors regulate ketone body metabolism via inter-organ crosstalk[J]. Diabetes Obes. Metab., 2019, 21(4): 801-811.
33	WANG J, HUANG X, LIU H, et al.. Empagliflozin ameliorates diabetic cardiomyopathy via attenuating oxidative stress and improving mitochondrial function[J/OL]. Oxid. Med. Cell. Longev., 2022, 2022: 1122494[2022-05-09]. .
34	SHAO Q, MENG L, LEE S, et al.. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats[J/OL]. Cardiovasc. Diabetol., 2019, 18(1): 165[2019-11-28]. .
35	KRISTENSEN S L, RØRTH R, JHUND P S, et al.. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials[J]. Lancet Diabetes Endocrinol., 2019, 7(10): 776-785.
36	VERMA S, MCGUIRE D K, BAIN S C, et al.. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials[J]. Diabetes Obes. Metab., 2020, 22(12): 2487-2492.
37	GIUGLIANO D, SCAPPATICCIO L, LONGO M, et al.. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs[J/OL]. Cardiovasc. Diabetol., 2021, 20(1): 189[2021-09-15]. .
38	ZHANG X, ZHANG Z, YANG Y, et al.. Alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function in diabetic rabbits[J/OL]. Cardiovasc. Diabetol., 2018, 17(1): 160[2018-12-27]. .
39	PHAM T K, NGUYEN T H T, YI J M, et al.. Evogliptin, a DPP-4 inhibitor, prevents diabetic cardiomyopathy by alleviating cardiac lipotoxicity in db/db mice[J]. Exp. Mol. Med., 2023, 55(4): 767-778.
40	FANG W J, LI X M, ZHOU X K, et al.. Resveratrol improves diabetic cardiomyopathy by preventing asymmetric dimethylarginine-caused peroxisome proliferator-activated receptor-γ coactivator-1α acetylation[J/OL]. Eur. J. Pharmacol., 2022, 936: 175342[2022-12-29]. .
41	XIONG Y, HAI C X, FANG W J, et al.. Endogenous asymmetric dimethylarginine accumulation contributes to the suppression of myocardial mitochondrial biogenesis in type 2 diabetic rats[J/OL]. Nutr. Metab., 2020, 17: 72[2020-08-24]. .
42	XIONG Y, HE Y L, LI X M, et al.. Endogenous asymmetric dimethylarginine accumulation precipitates the cardiac and mitochondrial dysfunctions in type 1 diabetic rats[J/OL]. Eur. J. Pharmacol., 2021, 902: 174081[2021-04-24]. .
43	MA T, HUANG X, ZHENG H, et al.. SFRP2 improves mitochondrial dynamics and mitochondrial biogenesis, oxidative stress, and apoptosis in diabetic cardiomyopathy[J/OL]. Oxid. Med. Cell. Longev., 2021, 2021: 9265016[2021-11-08]. .
44	YU L M, DONG X, XUE X D, et al.. Melatonin attenuates diabetic cardiomyopathy and reduces myocardial vulnerability to ischemia-reperfusion injury by improving mitochondrial quality control: role of SIRT6[J/OL]. J. Pineal Res., 2021, 70(1): e12698[2020-10-24]. .
45	CHANG X, ZHANG T, WANG J, et al.. SIRT5-related desuccinylation modification contributes to quercetin-induced protection against heart failure and high-glucose-prompted cardiomyocytes injured through regulation of mitochondrial quality surveillance[J/OL]. Oxid. Med. Cell. Longev., 2021, 2021: 5876841[2021-09-23]. .
46	LI Y, WEI X, LIU S L, et al.. Salidroside protects cardiac function in mice with diabetic cardiomyopathy via activation of mitochondrial biogenesis and SIRT3[J]. Phytother. Res., 2021, 35(8): 4579-4591.
47	KO T H, MARQUEZ J C, KIM H K, et al.. Resistance exercise improves cardiac function and mitochondrial efficiency in diabetic rat hearts[J]. Pflugers Arch. Eur. J. Physiol., 2018, 470(2): 263-275.
48	LI J, FENG Z, LU B, et al.. Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation[J/OL]. Biochem. Biophys. Rep., 2023, 34: 101444[2023-03-01]. .
49	WANG H, BEI Y, LU Y, et al.. Exercise prevents cardiac injury and improves mitochondrial biogenesis in advanced diabetic cardiomyopathy with PGC-1α and Akt activation[J]. Cell. Physiol. Biochem., 2015, 35(6): 2159-2168.

[1]	廖敏, 杨洛, 王珍, 郝亚荣. 松果菊苷对db/db糖尿病小鼠心肌的保护作用[J]. 生物技术进展, 2022, 12(1): 129-134.
[2]	廖敏, 杨洛, 王珍, 郝亚荣. 糖尿病心肌病发病机制的研究进展[J]. 生物技术进展, 2021, 11(6): 700-704.

线粒体生物合成在糖尿病心肌病中的研究进展

Research Progress of Mitochondrial Biosynthesis in Diabetes Cardiomyopathy

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 49

相关文章 2

编辑推荐

Metrics

本文评价